CoChat

A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma

Markovic, Svetomir N., Suman, Vera J., Rao, Ravi A., Ingle, James N., Kaur, Judith S., Erickson, Lori A., Pitot, Henry C., Croghan, Gary A., McWilliams, Robert R., Merchan, Jaime, Kottschade, Lisa A., Nevala, Wendy K., Uhl, Cindy B., Allred, Jacob, Creagan, Edward T. · 2007 · American Journal of Clinical Oncology
Cited by 109

The DOI matches its Crossref record.

Abstract

OBJECTIVES: Thrombospondins are natural inhibitors of angiogenesis, tumor metastases, and tumor growth (melanoma). ABT-510 is a synthetic analog of thrombospondin-1, well tolerated in phase I studies. We conducted a phase II trial evaluating the clinical efficacy of ABT-510 and its effects on biomarkers of angiogenesis and immunity in patients with metastatic melanoma (MM). PATIENTS AND METHODS: A 2-stage phase II clinical trial was conducted to assess the clinical efficacy, safety, and pharmacodynamic effects (angiogenesis and immunity) of ABT-510 in patients with stage IV melanoma. The primary endpoint was 18-week treatment failure rate. Patients self-administered 100 mg of ABT-510 subcutaneously twice daily. Blood samples were collected at baseline and every 3 weeks while on therapy. Eligible patients demonstrated measurable disease, good performance status and no evidence of intracranial metastases. Correlative laboratory studies evaluated biomarkers of angiogenesis and immunity. RESULTS: Twenty-one patients were enrolled. Most patients were stage M1c (71%) and all had prior therapy for MM. Only 3 of the first 20 patients enrolled were progression free and on treatment at 18 weeks resulting in early termination of the study. Decreases in peripheral blood VEGF-A levels and VEGF-C levels, and CD146 and CD34/133 counts relative to pretreatment were detected. Limited changes in antitumor T cell immunity were observed. CONCLUSIONS: ABT-510 therapy administered at 100 mg twice/day in patients with MM did not demonstrate definite clinical efficacy. Further dose escalation or combination with cytotoxic therapy may be more effective therapeutically.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.coc.0000256104.80089.35

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 109

Metadata

Authors
Markovic, S. N., Suman, V. J., Rao, R. A., Ingle, J. N., Kaur, J. S., Erickson, L. A., Pitot, H. C., Croghan, G. A., McWilliams, R. R., Merchan, J., Kottschade, L. A., Nevala, W. K., Uhl, C. B., Allred, J., & Creagan, E. T.
Venue
American Journal of Clinical Oncology
Published
2007-06
Volume
30
Issue
3
Pages
303-309
ISSN
0277-3732 (ISSN-L)
OpenAlex
W2065468070
Cited by
109
References
0
FWCI
3.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma. https://app.cochat.ai/papers/10.1097/01.coc.0000256104.80089.35
The paper
Markovic, S. N., Suman, V. J., Rao, R. A., Ingle, J. N., Kaur, J. S., Erickson, L. A., Pitot, H. C., Croghan, G. A., McWilliams, R. R., Merchan, J., Kottschade, L. A., Nevala, W. K., Uhl, C. B., Allred, J., & Creagan, E. T. (2007). A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma. American Journal of Clinical Oncology. https://doi.org/10.1097/01.coc.0000256104.80089.35

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.